Nurix Therapeutics Inc

NASDAQ:NRIX   4:00:00 PM EDT
14.70
+0.16 (+1.10%)
7:16:35 PM EDT: $14.95 +0.25 (+1.70%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)718.74M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$17.08 Million
Adjusted EPS-$0.76
See more estimates
10-Day MA$13.74
50-Day MA$11.02
200-Day MA$8.99
See more pivots

Nurix Therapeutics Inc Stock, NASDAQ:NRIX

1700 Owens Street, Suite 205, San Francisco, California 94158
United States of America
Phone: +1.415.660.5320
Number of Employees: 284

Description

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rap�©, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.